Study compares Nepafenac, Intravitreal Triamcinolone and no
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to compare the efficacy of topical nepafenac 0.1% versus intravitreal triamcinolone acetonide (IVTA) at the conclusion of vitrectomy surgery versus no adjuvant therapy (NAT) in improving macular morphology post-operatively in patients undergoing vitrectomy for epiretinal membrane (ERM), as measured by optical coherence tomography (OCT) imaging and best-corrected visual acuity (BCVA).

80 patients with idiopathic ERM who were scheduled for vitrectomy surgery were randomly assigned to receive IVTA (4 mg/0.1 cc) at the conclusion of surgery, topical nepafenac sodium 0.1 percent TID for 1 month postoperatively, or no adjuvant therapy (NAT). Before surgery, OCT imaging, best-corrected visual acuity, and intraocular pressure (IOP) were all assessed, as well as one and two months later.

Results:
--Although all three groups showed reduction in macular thickness post-operation, the NAT group showed the most improvement, with a reduction of 136.18 ± 29.84 microm at two months.

--There was no statistically significant difference in macular thickness between the groups at each time point.

--The NAT group also had the best recovery in BCVA with an improvement of 0.207 logMAR (10.35 letters) at two months post-operation.

--There was no statistically significant difference in BCVA between the groups.

--There was statistically significant difference in the IOP between the three groups, only at 1 month visit.

--The IVTA group had the highest rise in average IOP at both 1 and 2 months post-operation (2.72 and 1.58 mmHg, respectively).

Conclusively, there was no advantage in the use of topical nepafenac or IVTA for post-vitrectomy ERM surgery.

Source: https://journals.lww.com/glaucomajournal/Abstract/9000/Efficacy_and_Safety_of_Repeated_Micropulse.97584.aspx
Like
Comment
Share